A retrospective evaluation of single agent bevacizumab in adults with recurrent 
glioblastoma (GBM) with an objective of determining progression free survival 
(PFS). There is no standard therapy for recurrent GBM after failure of 
alkylator-based chemotherapy. A total of 50 adults, ages 36-70 years (median 
64), with recurrent GBM were treated. All patients had previously been treated 
with surgery, concurrent radiotherapy and temozolomide, post-radiotherapy 
temozolomide and in 34 patients, one salvage regimen (PCV: 21, cyclophosphamide: 
13). A total of 13 patients underwent repeat surgery. Patients were treated at 
first or second recurrence with bevacizumab, once every 2 weeks, defined as a 
single cycle. Neurological evaluation was performed every 2 weeks and 
neuroradiographic assessment following the initial 2 cycles of bevacizumab and 
subsequently after every 4 cycles of bevacizumab. A total of 468 cycles of 
bevacizumab (median 2 cycles; range 1-30) was administered. Bevacizumab-related 
toxicity included fatigue (16 patients; 4 grade 3), leukopenia (9; 1 grade 3), 
anemia (5; 0 grade 3), hypertension (7; 1 grade 3), deep vein thrombosis (4; 1 
grade 3) and wound dehiscence (2; 1 grade 3). 21 patients (42%) demonstrated a 
partial radiographic response and 29 (58%) progressive disease following 1-2 
cycles of bevacizumab. Time to tumor progression ranged from 0.5 to 15 months 
(median: 1.0 months). Survival ranged from 2 to 17 months (median: 8.5 months). 
6-month and 12-month PFS were 42% and 22% respectively. Single agent bevacizumab 
demonstrated efficacy and acceptable toxicity in this cohort of adults with 
recurrent alkylator-refractory GBM.